Non-coronary atherosclerotic cardiovascular disease in patients with familial hypercholesterolaemia

References

• Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478–3490a.
   PubMed Web of Science ®Google Scholar
• Wilemon KA, Patel J, Aguilar-Salinas C, et al. Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action. JAMA Cardiol. 2020;5(2):217–229.
   PubMed Web of Science ®Google Scholar
• Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425–2437.
   PubMed Web of Science ®Google Scholar
• Usifo E, Leigh SE, Whittall RA, et al. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann Hum Genet. 2012;76(5):387–401.
   PubMed Web of Science ®Google Scholar
• Iacocca MA, Wang J, Sarkar S, et al. Whole-Gene duplication of PCSK9 as a novel genetic mechanism for severe familial hypercholesterolemia. Can J Cardiol. 2018;34(10):1316–1324.
   PubMed Web of Science ®Google Scholar
• Akioyamen LE, Genest J, Shan SD, et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open. 2017;7(9):e016461.
   PubMed Web of Science ®Google Scholar
• Programme WHOHG. Familial hypercholesterolaemia (FH): report of a second WHO consultation, Geneva. 4 September 1998. Geneva: WHO; 1999.
   Google Scholar
• Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific steering committee on behalf of the Simon Broome Register Group. BMJ. 1991;303(6807):893–896.
   PubMedGoogle Scholar
• Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72(2):171–176.
   PubMed Web of Science ®Google Scholar
• Masana L, Zamora A, Plana N, et al. Incidence of cardiovascular disease in patients with familial hypercholesterolemia phenotype: analysis of 5 years follow-up of real-world data from more than 1.5 million patients. J Clin Med. 2019;8(7):1080.
   PubMed Web of Science ®Google Scholar
• Iyen B, Qureshi N, Kai J, et al. Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: a cohort study. Atherosclerosis. 2019;287:8–15.
   PubMed Web of Science ®Google Scholar
• Perak AM, Ning H, de Ferranti SD, et al. Long-Term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype. Circulation. 2016;134(1):9–19.
   PubMed Web of Science ®Google Scholar
• Bea AM, Civeira F, Jarauta E, et al. Association between the presence of carotid artery plaque and cardiovascular events in patients with genetic hypercholesterolemia. Rev Esp Cardiol. 2017;70(7):551–558.
   PubMed Web of Science ®Google Scholar
• Rallidis LS, Kosmas N, Tsirebolos G, et al. Prevalence of heterozygous familial hypercholesterolemia and combined hyperlipidemia phenotype in very young survivors of myocardial infarction and their association with the severity of atheromatous burden. J Clin Lipidol. 2019;13(3):502–508.
   PubMed Web of Science ®Google Scholar
• Bos S, Duvekot MH, Ten Kate GR, et al. Carotid artery plaques and intima medial thickness in familial hypercholesteraemic patients on long-term statin therapy: a case control study. Atherosclerosis. 2017;256:62–66.
   PubMed Web of Science ®Google Scholar
• Sharifi M, Higginson E, Bos S, et al. Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs polygenic hypercholesterolemia. Atherosclerosis. 2017;263:405–411.
   PubMed Web of Science ®Google Scholar
• Tada H, Kawashiri MA, Okada H, et al. Assessments of carotid artery plaque burden in patients with familial hypercholesterolemia. Am J Cardiol. 2017;120(11):1955–1960.
   PubMed Web of Science ®Google Scholar
• Walus-Miarka M, Czarnecka D, Kloch-Badelek M, et al. Carotid artery plaques - Are risk factors the same in men and women with familial hypercholesterolemia? Int J Cardiol. 2017;244:290–295.
   PubMed Web of Science ®Google Scholar
• Sun D, Zhou BY, Zhao X, et al. Lipoprotein(a) level associates with coronary artery disease rather than carotid lesions in patients with familial hypercholesterolemia. J Clin Lab Anal. 2018;32(7):e22442.
   PubMed Web of Science ®Google Scholar
• Sidhu PS, Naoumova RP, Maher VM, et al. The extracranial carotid artery in familial hypercholesterolaemia: relationship of intimal-medial thickness and plaque morphology with plasma lipids and coronary heart disease. J Cardiovasc Risk. 1996;3(1):61–67.
   PubMedGoogle Scholar
• Tatò F, Keller C, Schuster H, et al. Relation of lipoprotein(a) to coronary heart disease and duplexsonographic findings of the carotid arteries in heterozygous familial hypercholesterolemia. Atherosclerosis. 1993;101(1):69–77.
   PubMed Web of Science ®Google Scholar
• Cao YX, Liu HH, Sun D, et al. The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia. Atherosclerosis. 2018;277:7–14.
   PubMed Web of Science ®Google Scholar
• Bots ML. Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies. Curr Med Res Opin. 2006;22(11):2181–2190.
   PubMed Web of Science ®Google Scholar
• Braamskamp M, Langslet G, McCrindle BW, et al. Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: the CHARON study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label). Circulation. 2017;136(4):359–366.
   PubMed Web of Science ®Google Scholar
• Kusters DM, Wiegman A, Kastelein JJ, et al. Carotid intima-media thickness in children with familial hypercholesterolemia. Circ Res. 2014;114(2):307–310.
   PubMed Web of Science ®Google Scholar
• Noto N, Okada T, Abe Y, et al. Changes in the textural characteristics of intima-media complex in young patients with familial hypercholesterolemia: implication for visual inspection on B-mode ultrasound. J Am Soc Echocardiogr. 2011;24(4):438–443.
   PubMed Web of Science ®Google Scholar
• Narverud I, Retterstøl K, Iversen PO, et al. Markers of atherosclerotic development in children with familial hypercholesterolemia: a literature review. Atherosclerosis. 2014;235(2):299–309.
   PubMed Web of Science ®Google Scholar
• Tonstad S, Joakimsen O, Leren TP, et al. Does maternal or paternal heredity affect carotid atherosclerosis in children with familial hypercholesterolaemia? Acta Paediatr. 2007;89(12):1490–1492.
   Google Scholar
• Paraskevas KI, Eckstein H-H, Mikhailidis DP, et al. Rationale for screening selected patients for asymptomatic carotid artery stenosis. Curr Med Res Opin. 2020 [cited Jan 13]; [5 p.]. DOI:10.1080/03007995.2020.1713075.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111–188.
   PubMed Web of Science ®Google Scholar
• Ershova AI, Balakhonova TV, Meshkov AN, et al. Ultrasound markers that describe plaques are more sensitive than mean intima-media thickness in patients with familial hypercholesterolemia. Ultrasound Med Biol. 2012;38(3):417–422.
   PubMed Web of Science ®Google Scholar
• van Wissen S, Smilde TJ, de Groot E, et al. The significance of femoral intima-media thickness and plaque scoring in the atorvastatin versus simvastatin on atherosclerosis progression (ASAP) study. Eur J Cardiovasc Prev Rehabil. 2003;10(6):451–455.
   PubMedGoogle Scholar
• Wendelhag I, Wiklund O, Wikstrand J. Atherosclerotic changes in the femoral and carotid arteries in familial hypercholesterolemia. Ultrasonographic assessment of intima-media thickness and plaque occurrence. Arterioscler Thromb. 1993;13(10):1404–1411.
   PubMed Web of Science ®Google Scholar
• Waluś-Miarka M, Czarnecka D, Wojciechowska W, et al. Carotid plaques correlates in patients with familial hypercholesterolemia. Angiology. 2016;67(5):471–477.
   PubMed Web of Science ®Google Scholar
• Spengel FA, Kaess B, Keller C, et al. Atherosclerosis of the carotid arteries in young patients with familial hypercholesterolemia. Klin Wochenschr. 1988;66(2):65–68.
   PubMedGoogle Scholar
• Koga N, Watanabe K, Kurashige Y, et al. Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients. J Intern Med. 1999;246(1):35–43.
   PubMed Web of Science ®Google Scholar
• Paraskevas KI, Mikhailidis DP. More on carotid atherosclerosis and ezetimibe. Int Angiol. 2017;36(6):580–581.
   PubMed Web of Science ®Google Scholar
• Paraskevas KI, Veith FJ, Mikhailidis DP. Carotid intima-media thickness and ezetimibe: the end of a misunderstanding? Curr Vasc Pharmacol. 2011;9(4):381–384.
   PubMed Web of Science ®Google Scholar
• Junyent M, Gilabert R, Jarauta E, et al. Impact of low-density lipoprotein receptor mutational class on carotid atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis. 2010;208(2):437–441.
   PubMed Web of Science ®Google Scholar
• Akioyamen LE, Tu JV, Genest J, et al. Risk of ischemic stroke and peripheral arterial disease in heterozygous familial hypercholesterolemia: a meta-analysis. Angiology. 2019;70(8):726–736.
   PubMed Web of Science ®Google Scholar
• Barkas F, Elisaf M, Milionis H. Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: a systematic review and meta-analysis. Atherosclerosis. 2015;243(1):60–64.
   PubMed Web of Science ®Google Scholar
• Hovland A, Mundal LJ, Igland J, et al. Risk of ischemic stroke and total cerebrovascular disease in familial hypercholesterolemia. Stroke. 2019;50:172–174.
   PubMed Web of Science ®Google Scholar
• Elis A, Leventer-Roberts M, Bachrach A, et al. The characteristics of patients with possible familial hypercholesterolemia- screening a large payer/provider healthcare delivery system. QJM. 2019;hcz327.
   PubMed Web of Science ®Google Scholar
• Austin MA, Hutter CM, Zimmern RL, et al. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol. 2004;160(5):421–429.
   PubMed Web of Science ®Google Scholar
• Hutter CM, Austin MA, Humphries SE. Familial hypercholesterolemia, peripheral arterial disease, and stroke: a HuGE minireview. Am J Epidemiol. 2004;160(5):430–435.
   PubMed Web of Science ®Google Scholar
• Duell PB, Gidding SS, Andersen RL, et al. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: the CASCADE FH registry. Atherosclerosis. 2019;289:85–93.
   PubMed Web of Science ®Google Scholar
• Pereira C, Miname MH, Makdisse MR, et al. Peripheral arterial disease in heterozygous familial hypercholesterolemia. Atherosclerosis. 2015;242(1):174–178.
   PubMed Web of Science ®Google Scholar
• Perhoniemi V, Gylling H, Salmenkivi K. Peripheral atherosclerosis in familial hypercholesterolaemia. J Intern Med. 1989;225(6):379–383.
   PubMed Web of Science ®Google Scholar
• Pereira C, Miname M, Makdisse M, et al. Association of peripheral arterial and cardiovascular diseases in familial hypercholesterolemia. Arq Bras Cardiol. 2014;103(2):118–123.
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS. Noncoronary artery disease in familial hypercholesterolemia: underdiagnosis of peripheral arterial disease? Angiology. 2019;70(10):893–895.
   PubMed Web of Science ®Google Scholar
• Ferreira-Gonzalez I, Pinar-Sopena J, Ribera A, et al. Prevalence of calcific aortic valve disease in the elderly and associated risk factors: a population-based study in a Mediterranean area. Eur J Prev Cardiolog. 2013;20(6):1022–1030.
   PubMed Web of Science ®Google Scholar
• Fahed AC, Shibbani K, Andary RR, et al. Premature valvular heart disease in homozygous familial hypercholesterolemia. Cholesterol. 2017;2017:3685265.
   PubMedGoogle Scholar
• Vongpromek R, Bos S, Ten Kate GJ, et al. Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia. J Intern Med. 2015;278(2):166–173.
   PubMed Web of Science ®Google Scholar
• Ten Kate GR, Bos S, Dedic A, et al. Increased aortic valve calcification in familial hypercholesterolemia: prevalence, extent, and associated risk factors. J Am Coll Cardiol. 2015;66(24):2687–2695.
   PubMed Web of Science ®Google Scholar
• Smith JG, Luk K, Schulz CA, et al. Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. JAMA. 2014;312(17):1764–1771.
   PubMed Web of Science ®Google Scholar
• Okada H, Tada H, Hayashi K, et al. Aortic root calcification score as an independent factor for predicting major adverse cardiac events in familial hypercholesterolemia. J Atheroscler Thromb. 2018;25(7):634–642.
   PubMed Web of Science ®Google Scholar
• Akin I, Nienaber CA. Is there evidence for statins in the treatment of aortic valve stenosis? World J Cardiol . 2017;9(8):667–672.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Nicoll R, He YH, et al. The effect of statins on valve function and calcification in aortic stenosis: a meta-analysis. Atherosclerosis. 2016;246:318–324.
   PubMed Web of Science ®Google Scholar
• Thiago L, Tsuji SR, Nyong J, et al. Statins for aortic valve stenosis. Cochrane Database Syst Rev. 2016;9(9):CD009571.
   PubMed Web of Science ®Google Scholar
• Marco-Benedi V, Laclaustra M, Casado-Dominguez JM, et al. Aortic valvular disease in elderly subjects with heterozygous familial hypercholesterolemia: impact of lipid-lowering therapy. J Clin Med. 2019;8(12):2209.
   PubMed Web of Science ®Google Scholar
• Mundal LJ, Hovland A, Igland J, et al. Association of low-density lipoprotein cholesterol with risk of aortic valve stenosis in familial hypercholesterolemia. JAMA Cardiol. 2019;4(11):1156. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Vuorio A, Watts GF, Kovanen PT. Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia. Atherosclerosis. 2019;281:25–30.
   PubMed Web of Science ®Google Scholar
• Cao J, Steffen BT, Budoff M, et al. Lipoprotein(a) levels are associated with subclinical calcific aortic valve disease in white and black individuals: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2016;36(5):1003–1009.
   PubMed Web of Science ®Google Scholar
• Cegla J, Neely RDG, France M, et al. HEART UK consensus statement on Lipoprotein(a): a call to action. Atherosclerosis. 2019;291:62–70.
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Karras S, Lambrinoudaki I, et al. Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options. Int J Clin Pract. 2016;70(12):967–977.
   PubMed Web of Science ®Google Scholar
• Kotani K, Sahebkar A, Serban C, et al. Tibolone decreases Lipoprotein(a) levels in postmenopausal women: a systematic review and meta-analysis of 12 studies with 1009 patients. Atherosclerosis. 2015;242(1):87–96.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244–255. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Yagi K, Hifumi S, Nohara A, et al. Difference in the risk factors for coronary, renal and other peripheral arteriosclerosis in heterozygous familial hypercholesterolemia. Circ J. 2004;68(7):623–627.
   PubMed Web of Science ®Google Scholar
• Emanuelsson F, Nordestgaard BG, Benn M. Familial hypercholesterolemia and risk of peripheral arterial disease and chronic kidney disease. J Clin Endocrinol Metab. 2018;103(12):4491–4500.
   PubMed Web of Science ®Google Scholar
• Wagner M, Wanner C, Kotseva K, et al. Prevalence of chronic kidney disease and its determinants in coronary heart disease patients in 24 European countries: insights from the EUROASPIRE IV survey of the European Society of Cardiology. Eur J Prev Cardiolog. 2017;24(11):1168–1180.
   PubMed Web of Science ®Google Scholar
• Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765.
   PubMed Web of Science ®Google Scholar
• Wattanakit K, Folsom AR, Selvin E, et al. Kidney function and risk of peripheral arterial disease: results from the atherosclerosis risk in communities (ARIC) Study. J Am Soc Nephrol. 2007;18(2):629–636.
   PubMed Web of Science ®Google Scholar
• Harrison SC, Holmes MV, Burgess S, et al. Genetic association of lipids and lipid drug targets with abdominal aortic aneurysm: a meta-analysis. JAMA Cardiol. 2018;3(1):26–33.
   PubMed Web of Science ®Google Scholar
• Weng LC, Roetker NS, Lutsey PL, et al. Evaluation of the relationship between plasma lipids and abdominal aortic aneurysm: a Mendelian randomization study. PLOS One. 2018;13(4):e0195719.
   PubMed Web of Science ®Google Scholar
• Krogh HW, Mundal L, Holven KB, et al. Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death. Eur Heart J. 2016;37(17):1398–1405.
   PubMed Web of Science ®Google Scholar
• Kita Y, Shimizu M, Sugihara N, et al. Abdominal aortic aneurysms in familial hypercholesterolemia–case reports. Angiology. 1993;44(6):491–499.
   PubMed Web of Science ®Google Scholar
• Alonso R, Perez de Isla L, Muniz-Grijalvo O, et al. Familial hypercholesterolaemia diagnosis and management. Eur Cardiol. 2018;13(1):14–20.
   PubMed Web of Science ®Google Scholar
• Beppu S, Minura Y, Sakakibara H, et al. Supravalvular aortic stenosis and coronary ostial stenosis in familial hypercholesterolemia: two-dimensional echocardiographic assessment. Circulation. 1983;67(4):878–884.
   PubMed Web of Science ®Google Scholar
• Awan Z, Alrasadi K, Francis GA, et al. Vascular calcifications in homozygote familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2008;28(4):777–785.
   PubMed Web of Science ®Google Scholar
• Akioyamen LE, Genest J, Chu A, et al. Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: a systematic review and meta-analysis. J Clin Lipidol. 2019;13(1):15–30.
   PubMed Web of Science ®Google Scholar
• Aune D, Schlesinger S, Norat T, et al. Tobacco smoking and the risk of abdominal aortic aneurysm: a systematic review and meta-analysis of prospective studies. Sci Rep. 2018;8(1):14786.
   PubMed Web of Science ®Google Scholar
• Soljanlahti S, Autti T, Hyttinen L, et al. Compliance of the aorta in two diseases affecting vascular elasticity, familial hypercholesterolemia and diabetes: a MRI study. Vasc Health Risk Manag. 2008;4(5):1103–1109.
   PubMedGoogle Scholar
• Schmitz SA, O’Regan DP, Fitzpatrick J, et al. Quantitative 3T MR imaging of the descending thoracic aorta: patients with familial hypercholesterolemia have an increased aortic plaque burden despite long-term lipid-lowering therapy. J Vasc Interv Radiol. 2008;19(10):1403–1408.
   PubMed Web of Science ®Google Scholar
• Soljanlahti S, Autti T, Vuorio AF, et al. Aorta of young and middle-aged heterozygous familial hypercholesterolemia patients shows no functional or morphological impairment assessed by MRI. VHRM. 2008;4(4):923–929.
   Google Scholar
• Caballero P, Alonso R, Rosado P, et al. Detection of subclinical atherosclerosis in familial hypercholesterolemia using non-invasive imaging modalities. Atherosclerosis. 2012;222(2):468–472.
   PubMed Web of Science ®Google Scholar
• Fernandez-Ortiz A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol. 1994;23(7):1562–1569.
   PubMed Web of Science ®Google Scholar
• Hovland A, Mundal LJ, Igland J, et al. Increased risk of heart failure and atrial fibrillation in heterozygous familial hypercholesterolemia. Atherosclerosis. 2017;266:69–73.
   PubMed Web of Science ®Google Scholar
• Lee H-J, Lee S-R, Choi E-K, et al. Low lipid levels and high variability are associated with the risk of new-onset atrial fibrillation. J Am Heart Assoc. 2019;8(23):e012771.
   PubMed Web of Science ®Google Scholar